Comparison
2p25 3 Microduplication Syndrome C6012304 vs 15q Overgrowth Syndrome
Clinical comparison between 2p25 3 Microduplication Syndrome and 15q Overgrowth Syndrome for differential diagnosis and treatment planning.
6 comparison axes
Onset
2p25 3 Microduplication Syndrome C6012304
0-5
15q Overgrowth Syndrome
0-0
Onset patterns differ
Severity
2p25 3 Microduplication Syndrome C6012304
severe
15q Overgrowth Syndrome
moderate
Different severity levels
Chronic
2p25 3 Microduplication Syndrome C6012304
Chronic
15q Overgrowth Syndrome
Chronic
Differing course
Communicable
2p25 3 Microduplication Syndrome C6012304
No
15q Overgrowth Syndrome
No
Different transmission
Body System
2p25 3 Microduplication Syndrome C6012304
congenital
15q Overgrowth Syndrome
congenital
Same/different system
Category
2p25 3 Microduplication Syndrome C6012304
rare-disease
15q Overgrowth Syndrome
genetic
Different category
Bottom line
2p25-3-microduplication-syndrome-C6012304 and 15q-overgrowth-syndrome-C4749920 differ in severity, etiology
Key differentiating points
Findings that most reliably separate the two conditions at the bedside or in the workup.
| Feature | 2p25 3 Microduplication Syndrome C6012304 | 15q Overgrowth Syndrome | Discriminating power |
|---|---|---|---|
| Genomic locus | Extra material involving chromosome 2p25.3. | Name implies chromosome 15q; exact interval is not supplied. | High |
| Growth pattern | Not defined as overgrowth; features vary with involved genes. | Overgrowth is suggested by the name but not established here. | Moderate |
| Congenital or developmental findings | May vary widely and can be severe. | Specific findings are absent from the source data. | Low |
When to favor each condition
Choose 2p25 3 Microduplication Syndrome C6012304 when
Confirmed gain at 2p25.3
The reported locus matches the left concept.
High
Presentation from birth through early childhood
The supplied onset range is 0–5 years, without a required overgrowth pattern.
Moderate
Severe variable congenital course
Severity is listed as severe, but individual features still need confirmation.
Low
Choose 15q Overgrowth Syndrome when
Confirmed 15q change plus documented overgrowth
Both the named region and growth pattern would support consideration.
Moderate
Neonatal congenital presentation
The axis lists onset at birth, but clinical details are absent.
Low
Moderate reported course
Supplied severity is moderate, which alone cannot establish the diagnosis.
Low
How key tests differ
| Test | 2p25 3 Microduplication Syndrome C6012304 | 15q Overgrowth Syndrome | Interpretation |
|---|---|---|---|
| Chromosomal microarray | May identify a 2p25.3 copy-number gain. | Should be reviewed for a relevant 15q gain if suspected. | Locus, size, and genes must be reported; an abnormal result is not the full diagnosis. |
| Karyotype | A small duplication may not be visible. | A small 15q change may likewise be missed. | A normal karyotype does not exclude either condition. |
| Gene-content review | Interpretation depends on duplicated 2p25.3 genes. | Relevant 15q genes are not specified in this source. | Genetics review is required; pathogenicity cannot be inferred from the name. |
Prognosis comparison
2p25 3 Microduplication Syndrome C6012304
- Outcome
- Chronic congenital condition with variable, unquantified outcome.
- Factors
- Duplication size, gene content, and associated anomalies.
15q Overgrowth Syndrome
- Outcome
- A chronic course is indicated, but outcome data are not established.
- Factors
- Unspecified 15q content and any documented growth findings.
Time frame: From birth or early childhood onward; exact course unknown.
No mortality rate or uniform prognosis is established for either concept.
Complications comparison
| Complication | Presentation |
|---|---|
| Developmental difficulty | Possible but not uniform. Not established by the supplied data. Assess development individually rather than from the label. |
| Growth disturbance | No specific growth pattern is established. Overgrowth is implied only by the concept name. Use measured growth data and clinician interpretation. |
| Other congenital anomalies | May occur and vary with gene content. No anomaly list is supplied. Targeted evaluation should follow genetics advice. |
Patient education highlights
- HighConfirm the finding
Ask which chromosomal region, genes, test, and report support the result.
- HighExpect variability
Effects can differ between people; one case does not predict another.
- MediumCare planning
Management is symptom-focused. No treatment dose or cure is established here.